Clinical Trial

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

Study acronym: CIMcare
Completed Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-01
notable Primary completion moved earlier: 2029-09-19 -> 2026-04-09 2026-04-02
minor Completion moved earlier: 2034-08-15 -> 2026-07-02 2026-04-02
Trial Details
NCT Number NCT04123795
Lead Sponsor UCB Biopharma SRL
Conditions Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
Enrollment 49 participants
Start Date 2020-01-21
Primary Completion 2026-04-09 (estimated)
Study Completion 2026-07-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-04